School of Pediatrics, University of Cagliari, Cagliari, Italy.
Eur Rev Med Pharmacol Sci. 2021 Apr;25(8):3325-3337. doi: 10.26355/eurrev_202104_25744.
Since the reports in Wuhan (China), in December 2019, of the first cluster of cases of pneumonia caused by the new Coronavirus called 2019-nCoV or SARS-CoV-2, there has been a pandemic spread of the infection. By now, we have no specific therapy to counteract this emergency. The latest epidemiological data suggest that children are just as likely as adults to get infected by the virus. Most of them show mild clinical pictures or are completely asymptomatic, but there is an increased risk for severe disease in infancy (<12 months of age) and in children with underlying medical conditions. In this article, research achievements on the treatment of pediatric SARS-CoV-2 infection are examined.
自 2019 年 12 月中国武汉首次报告新型冠状病毒（2019-nCoV 或 SARS-CoV-2）引起的肺炎聚集性病例以来，该感染已呈全球大流行趋势。目前，我们尚无针对这种紧急情况的特效疗法。最新的流行病学数据表明，儿童和成人一样容易感染该病毒。他们大多数表现为轻症或完全无症状，但婴儿（<12 个月龄）和患有基础疾病的儿童患重症疾病的风险增加。本文对儿科 SARS-CoV-2 感染的治疗研究成果进行了考察。
